Streetbeat News

TELO

Telomir Pharmaceuticals Inc

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

5.10

Mkt cap

136M

Volume

305K

High

5.23

P/E Ratio

-8.18

52-wk high

9.39

Low

4.50

Div yield

N/A

52-wk low

3.11

Telomir Pharmaceuticals announced pre-clinical data for its age-reversal drug, Telomir-1, showing a 40% increase in telomerase activity and lengthened telomeres in human cells. The company provided endpoints for assessing the drug's effects in dogs and outlined plans for human and animal IND trials targeting osteoarthritis.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:39 pm

In Wednesday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals led the gainers with a 61.6% increase, while Acorda Therapeutics headed the losers with a 20.4% decrease. Other notable movers included Jaguar Health, Orgenesis, BioSig Technologies, and Telomir Pharmaceuticals on the gainers' side, and Kineta, DocGo, Biophytis, Yield10 Bioscience, and Eyenovia among the losers.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:31 pm

Telomir Pharmaceuticals has partnered with Argenta to conduct a study on the efficacy of Telomir-1 in treating osteoarthritis and other age-related diseases in canines. This groundbreaking study aims to explore the potential of reversing aging in dogs.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:35 pm

Telomir Pharmaceuticals announced the release of pre-clinical data for its lead development product, Telomir-1, which will be presented at the Global Longevity Federation Conference in Las Vegas on March 26th. The data shows that Telomir-1 can elongate telomere caps on human normal embryonic fibroblast cells, addressing telomere shortening, a major contributor to aging as reported by The New York Times.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 12:32 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Aptorum Gr, Nuvectis Pharma, and Bright Green were among the top gainers, with shares increasing by 47.1%, 23.65%, and 20.99% respectively. On the losing side, Spruce Biosciences saw a dramatic drop of 78% following its Q4 earnings report. Other notable decliners include Kintara Therapeutics and Nuvation Bio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 1:06 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Regulus Therapeutics led the gainers with an 84.8% increase, while Renalytix faced the largest drop among the losers, declining by 27.2%. Notably, Bioventus and CytomX Therapeutics released their Q4 earnings, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 1:06 pm

Telomir Pharmaceuticals presented pre-clinical data for its lead development product at a conference in Singapore, indicating progress in its research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 1:31 pm

Herbalife Ltd. (NYSE:HLF) shares plummeted by approximately 36% due to disappointing quarterly earnings, missing market expectations. The article also highlights significant movements in other stocks during Thursday's mid-day session, including notable gainers like JX Luxventure Limited and losers such as Treasure Global Inc.

Portfolio Pulse from Avi Kapoor

February 15, 2024 | 6:20 pm

AppLovin Corporation's shares surged by approximately 22% in pre-market trading after reporting Q4 earnings and sales that exceeded analyst expectations. Other stocks also showed significant movement in pre-market trading, with notable gainers including China Natural Resources, Inc., and JFrog Ltd., and losers like Treasure Global Inc., and Cineverse Corp.

Portfolio Pulse from Avi Kapoor

February 15, 2024 | 12:57 pm

Trading of Telomir Pharma shares, symbol TELO, has resumed after a temporary halt.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 4:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.